Comparative Pharmacology
Head-to-head clinical analysis: DYCLOPRO versus INDOCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYCLOPRO versus INDOCIN.
DYCLOPRO vs INDOCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diclofenac epolamine inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis and consequent inflammation, pain, and fever.
Indomethacin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever. It also decreases renal blood flow and may cause ductus arteriosus closure.
50 mg intravenously every 8 hours
25 mg orally 2-3 times daily; maximum 200 mg/day. Intravenous: 0.5-1 mg/kg as single dose for ductus arteriosus closure.
None Documented
None Documented
Terminal elimination half-life is approximately 2-4 hours in adults with normal renal function; may be prolonged in renal impairment (up to 8-12 hours).
Terminal elimination half-life approximately 4.5 hours (range 2.6–11.2 hours); prolonged in elderly and patients with hepatic impairment.
Primarily renal (approximately 70% as unchanged drug and metabolites); biliary/fecal excretion accounts for about 30%.
Renal (60% as unchanged drug and glucuronide conjugates), biliary/fecal (33% via enterohepatic circulation).
Category C
Category C
NSAID
NSAID